2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news -

Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally.

Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free.

In October 2022, PROVIREX announced a major expansion in Hamburg’s .